Cardiac toxicity of trastuzumab (Herceptin): implications for the design of adjuvant trials

JA Sparano - Seminars in oncology, 2001 - Elsevier
Trastuzumab (Herceptin; Genentech, South San Francisco, CA) is a humanized version of
the murine monoclonal antibody 4D5 that was recently approved for the treatment of
advanced breast cancer that overexpresses the HER2/neu oncogene. Cardiac toxicity was
an unexpected side effect of trastuzumab treatment in the pivotal trials that led to its
approval. The incidence of cardiac dysfunction was highly dependent on prior or concurrent
doxorubicin exposure. For patients with minimal prior anthracycline exposure, the risk of …